Extended Data Fig. 9: Treatments of αPD-1 and CSF1R inhibitor improve NASH pathologies.

a, Experimental schedule of the PLX3397 treatment on young (3-month-old, n = 5) and old (17.5-month-old, n = 5) wild type mice. The treatment of 40 mg/kgBW PLX3397 was administrated by oral-gavage twice per week in a total 3 weeks period. (All the male mice in each group were adapted in two independent cages.) b, The motor performance test of the indicated mice as in a. The staying time was recorded from starting rotation of rotarod model to the mouse falling on the switch. c, The grip strength test of mice as in a. d, The quantification of alveolar size of the indicated mice as in a. Representative images (H&E staining) were shown in the right panels. e, Experimental schedule of the αPD1 and PLX3397 treatment on wild type mice fed with normal diet or CDA-HFD. (n = 5 for each group) f, The serum levels of AST, ALT, and LDH from the mice as in e. g, Representative images (lower panels: H&E staining) and quantification of lipid drop area (upper panel) of livers from the indicated mice as in e. h, The Sirius red staining of livers from the mice as in e. The representative images were shown in lower panels. Scale bars, 100 μm. Data are presented as means ±SEM of independent experiments. Two-way ANOVA with Sidak’s test was performed. ****P < 0.0001. The precise p-values were described in Methods.